All filters
Slidesets
Pharmacogenetics of Efavirenz Discontinuation for Central Nervous System Symptoms at a Southeastern United States Clinic May Differ by Race - Paul Leger, MD, MPH
Presented at:
International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016
Slidesets
Virologic and Immunologic Responses to Raltegravir and Dolutegravir in GALT of HIV+ Men and Women - Michael Weber, PharmD
Presented at:
International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016
Slidesets
FDA Perspective on "oral run-in" phase - Dr. Yodit Belew
Presented at:
International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016
Slidesets
ViiV - Cabotegravir - Bill Spreen, PharmD
Presented at:
International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016
Slidesets
Target Concentrations - Angela Kashuba, PharmD
Presented at:
International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016
Slidesets
Janssen - Rilpivirine - Herta Crauwels, PhD
Presented at:
International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016
Slidesets
Efficacy of once-weekly MK-8591 in SIV infected rhesus macaques - Dr. Matthew Rizk
Presented at:
International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016
Slidesets
In silico pharmacokinetic/pharmacodynamic simulation of long acting tenofovir injectable formulation for pre exposure prophylaxis strategies - Dr. Paul Curley
Presented at:
International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016
Slidesets
Looking Backwards: Hormonal Contraception and ART - Kimberly Scarsi, PharmD, MS, FCCP
Presented at:
International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016
Slidesets
Will we see the Back of DDIs? - Catia Marzolini, PharmD, PhD
Presented at:
International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016
Slidesets
Pharmacogenetics - Back to reality - Andrew Owen, BSS, MSC, PhD, FSB
Presented at:
International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016
Slidesets
The ‘Back Side’ of Compartments - Saye Khoo, MD, PhD
Presented at:
International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016
Slidesets
Back-terial co-infections - Mohammed Lamorde, FRCP, PhD
Presented at:
International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016
Slidesets
Specific Complex Interactions (mechanic presentation) - David Burger, PharmD, PhD
Presented at:
International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016
Slidesets
PBPK/PD Modeling and Simulations to Guide Dose Recommendation of Amlodipine after Co-administration with Viekirax or Viekira Pak - Dwaipayan Mukherjee, PhD
Presented at:
International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016
Slidesets
Backing up clinical data with modelling - Marco Siccardi, PhD
Presented at:
International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016
Slidesets
Effects of Sofosbuvir/Ribavirin Treatment and ITPA Phenotype on Endogenous Purines - Dr. Leah Jimmerson
Presented at:
International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016
Slidesets
Rifampin (RIF) Decreases Cabotegravir (CAB) Exposure following Oral Coadministration - Dr. Susan Ford
Presented at:
International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016
Slidesets
Increased Tenofovir Diphosphate in Red Blood Cells, but Not Tenofovir in Plasma, with Sofosbuvir and Ribavirin - Dr. Christine MacBrayne
Presented at:
International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016
Slidesets
MK-3682, a HCV NS5B Inhibitor with a Broad Spectrum of HCV Genotypic Activity, Demonstrates Potent Antiviral Activity in Genotypes -1,-2, and -3 HCV-Infected Patients - Dr. Nancy Kim
Presented at:
International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016
Slidesets
Pharmacokinetics of Darunavir, Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir and Ribavirin in Adults Infected with Hepatitis C Virus (HCV) Genotype (GT) 1 and Human Immunodeficiency Virus Type 1 (HIV-1) - Dr. Jennifer King
Presented at:
International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016
Slidesets
Physiologically-based simulation of daclatasvir pharmacokinetics with antiretroviral inducers and inhibitors of cytochrome P450 and drug transporters - Dr. Timothy Eley
Presented at:
International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016
Slidesets
Pharmacokinetics of Dolutegravir after Switching to Abacavir/Dolutegravir/Lamivudine from an Efavirenz Based Regimen: A PK Substudy from Striiving - Dr. Jeff de Wet
Presented at:
International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016
Slidesets
A Clinically Meaningful Drug-Drug Interaction Observed Between ZepatierTM (Grazoprevir/Elbasvir) and Stribild® HIV Fixed-Dose Combination in Healthy Subjects - Dr. Hwa-Ping Feng
Presented at:
International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016